BACK

Improving biosafety

Pioneer in the use of nanofiltration

Since its formation in 1994 LFB has been an innovative player in the field of biosafety.
In 1995 LFB was the first pharmaceutical company to use nanofiltration in its processes for manufacturing plasma-derived medicinal products. Nanofiltration is a molecular filtration technique based on pore size, which has proven efficacy in eliminating viruses and reducing the risk from prions.

 

Pioneer in plasma quality before fractionation.

In 1996 LFB was also the first manufacturer to use PCR (polymerase chain reaction) for detecting parvovirus B19 in plasma for fractionation. PCR is a technique for detecting nucleic acids, which means that viruses can be detected before antibodies to those viruses appear. Since then, PCR has been used for all the plasma received by LFB for fractionation and also to detect HCV, HBV, HAV and HIV in addition to parvovirus B19.

 

Biosafety for innovation

Using the technological innovations it makes, such as the rPRO™ platform or EMABling®, LFB deploys the most advanced techniques for ensuring the biosafety of recombinant medicinal products.
In the emerging field of advanced therapies, the advent of personalised medicine on an industrial scale, with CELLforCURE, is accompanied by the implementation of strict measures, specific to that biotherapy segment, to ensure the biosafety of injected treatment given to patients within a few hours or days of production.

See also

Comprendre la nanofiltration

0:17

Understanding nanofiltration

Improving the biosafety of LFB’s plasma derivatives

3:20

Ensuring the biosafety of LFB’s plasma derivatives